Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Laboratory Science

Background:

• Antiplatelet therapy (aspirin and clopidogrel) is standard for cardiovascular disease (CVD).
• Some patients have adverse cardiac events despite antiplatelet therapy, potentially due to low drug responsiveness.
• Reported incidence of low responsiveness varies widely (1-45%) due to inconsistent testing methods.

Purpose of the Study:

• To review laboratory testing of antiplatelet response to aspirin and clopidogrel.
• To examine the prevalence, mechanisms, and clinical significance of low antiplatelet response.
• To explore alternative strategies for optimizing antiplatelet therapy in non-responsive patients.

Main Methods:

• Review of literature on antiplatelet drug response testing.
• Analysis of studies investigating the link between low responsiveness and cardiovascular events.
• Discussion of diagnostic challenges and therapeutic implications.

Main Results:

• Low responsiveness to aspirin or clopidogrel is linked to increased cardiovascular events.
• Evidence for this association is stronger for clopidogrel than aspirin.
• No established therapeutic approach currently exists for managing low antiplatelet response.

Conclusions:

• Low responsiveness to antiplatelet agents is a significant clinical concern in CVD.
• Standardized testing and validated therapeutic strategies are needed.
• Further research is required to optimize treatment for patients with suboptimal antiplatelet response.